Premium
IDELALISIB PLUS ANTI‐CD20 USED SECOND LINE SHOWS IMPROVED PFS AND COMPARABLE SAFETY COMPARED TO LATER LINE THERAPY OF RELAPSED CLL
Author(s) -
Brown J.R.,
Chan R.J.,
Xing G.,
Bhargava P.,
Ruzicka B.,
O'Brien S.M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.55_2631
Subject(s) - medicine , idelalisib , ofatumumab , adverse effect , regimen , rituximab , leukemia , chronic lymphocytic leukemia , lymphoma , ibrutinib